Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Review article: diagnosis and treatment of non-alcoholic fatty liver disease Oh MK; Winn J; Poordad FAliment Pharmacol Ther 2008[Sep]; 28 (5): 503-22BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent condition affecting adults and children, leading to significant morbidity. It is often associated with the metabolic syndrome, although multiple pathogenetic mechanisms have been suggested. In the coming decades, it promises to be the leading cause of liver disease in industrial countries. AIM: To provide a comprehensive, updated review of diagnosis and management of NAFLD and to appraise the evolution of new modalities in these areas. METHODS: An Ovid MEDLINE search was performed to identify pertinent original research and review articles. Selected references in these articles were also evaluated. RESULTS: The diagnosis of hepatic steatosis and steatohepatitis or non-alcoholic steatohepatitis (NASH) is not yet possible without liver biopsy. This is impractical given the large numbers affected by the condition. Current therapy has focused on improving insulin resistance and mediators of inflammation, factors probably associated with disease progression. CONCLUSIONS: There are no proven non-invasive diagnostic modalities to distinguish NAFLD and NASH, but new biomarker panels are approximating the liver biopsy in accuracy. Therapeutic targets of drug development are in early stages, but a multifaceted approach will probably yield several treatment options in the years to come.|Adult[MESH]|Aged[MESH]|Aspartate Aminotransferases/*metabolism[MESH]|Fatty Liver/*diagnosis/therapy[MESH]|Female[MESH]|Humans[MESH]|Insulin Resistance/physiology[MESH]|Liver Cirrhosis/diagnosis/etiology[MESH]|Male[MESH]|Metabolic Syndrome/complications[MESH]|Middle Aged[MESH]|Obesity/complications[MESH]|Oxidative Stress/physiology[MESH]|Up-Regulation/physiology[MESH] |
